|
Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM). |
|
|
Honoraria - AstraZeneca; Clovis Oncology; Lilly; Pfizer; Roche |
Consulting or Advisory Role - Lilly |
|
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Caris Life Sciences |
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate |
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Cerulean Pharma; Janssen Biotech; Labceutics; Pfizer |
Speakers' Bureau - Bayer; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi |
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology |
|
|
Employment - Boehringer Ingelheim |
|
|
Employment - Boehringer Ingelheim |
|
|
Employment - Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Boehringer Ingelheim |